1. Signaling Pathways
  2. MAPK/ERK Pathway
    Stem Cell/Wnt
  3. ERK
  4. ERK2 Isoform

ERK2

 

ERK2 Related Products (47):

Cat. No. Product Name Effect Purity
  • HY-12028
    PD98059
    Inhibitor 99.94%
    PD98059 is a potent and selective MEK inhibitor with an IC50 of 5 µM.
  • HY-18723
    Yoda 1
    Activator 99.98%
    Yoda 1 is a potent and selective Piezo1 agonist.
  • HY-50846
    SCH772984
    Inhibitor 98.69%
    SCH772984 is a highly selective and ATP-competitive ERK inhibitor, with IC50s of 4 and 1 nM for ERK1 and ERK2, respectively.
  • HY-15947
    Ravoxertinib
    Inhibitor 99.75%
    Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with an IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.
  • HY-N0003
    Honokiol
    Activator 99.90%
    Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules.
  • HY-151367
    SHR2415
    Inhibitor
    SHR2415 is a highly potent, selective and orally active ERK1/2 inhibitor.
  • HY-151634
    Syk-IN-6
    Inhibitor
    Syk-IN-6 is an inhibitor of the lipid-SH2 domain interaction, control the cellular activity of kinases containing SH2 domain.
  • HY-P3513
    β-Neo-Endorphin
    Activator
    β-Neo-Endorphin is an endogenous opioid peptide.
  • HY-15816
    Ulixertinib
    Inhibitor 99.95%
    Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2.
  • HY-N0431
    Astragaloside IV
    Inhibitor ≥98.0%
    Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.
  • HY-N2329
    Piperlongumine
    Inhibitor 98.09%
    Piperlongumine is a alkaloid, possesses ant-inflammatory, antibacterial, antiangiogenic, antioxidant, antitumor, and antidiabetic activities.
  • HY-101494
    Temuterkib
    Inhibitor 99.88%
    Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays.
  • HY-12275
    FR 180204
    Inhibitor 99.64%
    FR 180204 is an ATP-competitive and selective ERK inhibitor.
  • HY-111407
    MK-8353
    Inhibitor
    MK-8353 (SCH900353) is a potent, selective and orally available ERK1/2 inhibitor, with IC50s of 23.0 nM and 8.8 nM, respectively; MK-8353 has antitumor activity.
  • HY-112181
    KO-947
    Inhibitor 99.45%
    KO-947 is a potent and selective inhibitor of ERK1/2 kinases with potential utility in MAPK pathway dysregulated tumors.
  • HY-14178
    VX-11e
    Inhibitor 99.17%
    VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK with Ki < 2 nM.
  • HY-N2312
    Mogrol
    Inhibitor 99.25%
    Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.
  • HY-111483
    Tizaterkib
    Inhibitor 99.71%
    Tizaterkib (AZD0364) is a potent and selective ERK2 inhibitor extracted from patent WO2017080979A1, compound example 18, has an IC50 of 0.6 nM.
  • HY-136579
    ERK-IN-3
    Inhibitor 99.02%
    ERK-IN-3 is a potent and orally active inhibitor of ERK.
  • HY-114491
    Rineterkib
    Inhibitor 99.21%
    Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway.